Medicare Part D coverage · tadalafil · RxCUI 2613569

tadalafil 4 MG/ML Oral Suspension [Tadliq]

Per the CMS 2026 Part D formulary file, tadalafil 4 MG/ML Oral Suspension [Tadliq] is covered by 33 Medicare Part D plans (0.7% of enrollable products), averaging Tier 4.3, with prior authorization required on 100% of covering formularies.

0.7%
Plan coverage
33
Plans covering
T4.3
Avg tier
100%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for tadalafil 4 MG/ML Oral Suspension [Tadliq]

Per the CMS 2026 Part D formulary file, tadalafil 4 MG/ML Oral Suspension [Tadliq] (RxNorm concept RXCUI 2613569, generic name tadalafil) appears on 16 distinct formulary files spanning 33 Medicare Part D plan offerings - 0.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.3.

Real-world access to tadalafil 4 MG/ML Oral Suspension [Tadliq] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 75% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 74,638 Part D beneficiaries filled tadalafil 4 MG/ML Oral Suspension [Tadliq] in 2023, with total plan-and-beneficiary spending of $95,218,190 and an average per-beneficiary annual cost of $1,275.73. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry tadalafil 4 MG/ML Oral Suspension [Tadliq] today.

Coverage Details

Formularies covering
16
Plans covering
33
Coverage rate
0.7%
Tier range
Tier 1 – Tier 5
Average tier
Tier 4, Non-Preferred

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
75% of formularies

2023 Medicare Spending

Beneficiaries
74,638
Total spending
$95,218,190
Avg per beneficiary
$1,275.73

Tier Distribution Across Plans

3 plans
Tier 1, Preferred Generic
1 plans
Tier 2, Generic
29 plans
Tier 5, Specialty

Medicare Advantage Plans (MA-PD) Covering tadalafil 4 MG/ML Oral Suspension [Tadliq]

33 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
SeniorCare Complete (HMO D-SNP) South Country Health Alliance T1 Yes $0 MN
AbilityCare (HMO D-SNP) South Country Health Alliance T1 Yes $0 MN
Alameda Alliance Wellness (HMO D-SNP) Alameda Alliance FOR Health T1 Yes $0 CA
CalOptima Health OneCare Complete (HMO D-SNP) Orange County Health Authority T2 Yes $0 CA
Select Health Medicare Essential (HMO) Selecthealth, Inc. T5 Yes $0 UT
Select Health Medicare Essential (HMO) Selecthealth, Inc. T5 Yes $0 NV
Select Health Medicare Dual (HMO D-SNP) Selecthealth, Inc. T5 Yes $0 UT
Select Health Medicare Essential (HMO) Selecthealth, Inc. T5 Yes $0 UT
Select Health Medicare + Kroger (HMO) Selecthealth, Inc. T5 Yes $0 NV
Select Health Medicare + Kroger (HMO) Selecthealth, Inc. T5 Yes $0 UT
Select Health Medicare Essential (HMO) Selecthealth, Inc. T5 Yes $0 CO
Select Health Medicare Essential (HMO) Selecthealth, Inc. T5 Yes $0 CO
Select Health Medicare + Kroger (HMO) Selecthealth, Inc. T5 Yes $0 CO
Select Health Medicare Flex (HMO) Selecthealth, Inc. T5 Yes $0 CO
Select Health Medicare + Kroger (HMO) Selecthealth, Inc. T5 Yes $0 CO
Select Health Medicare Active (HMO) Selecthealth, Inc. T5 Yes $0 CO
Select Health Medicare Dual (HMO D-SNP) Selecthealth, Inc. T5 Yes $0 NV
Select Health Medicare Wellness (HMO) Selecthealth, Inc. T5 Yes $0 NV
Troy Medicare (HMO) Troy Health, Inc. T5 Yes $0 NC
Troy Medicare for Dual-eligible Beneficiaries (HMO D-SNP) Troy Health, Inc. T5 Yes $0 NC
Show the next 13 plans
Contra Costa Health Care Plus (HMO D-SNP) Contra Costa County Medical Service DBA Contra Costa Health T5 Yes $0 CA
Keystone First VIP Choice (HMO D-SNP) Vista Health Plan, Inc. T5 Yes $0 PA
AmeriHealth Caritas VIP Care (HMO D-SNP) Vista Health Plan, Inc. T5 Yes $0 PA
First Choice VIP Care (HMO D-SNP) Select Health OF South Carolina, Inc. T5 Yes $0 SC
AmeriHealth Caritas VIP Care (HMO D-SNP) AmeriHealth Caritas VIP Next, Inc. T5 Yes $0 DE
AmeriHealth Caritas VIP Care Choice (HMO D-SNP) AmeriHealth Caritas VIP Next, Inc. T5 Yes $0 DE
AmeriHealth Caritas VIP Care (HMO D-SNP) Amerihealth Caritas Florida, Inc. T5 Yes $0 FL
AmeriHealth Caritas VIP Care (HMO D-SNP) Amerihealth Caritas Louisiana, Inc. T5 Yes $0 LA
AmeriHealth Caritas VIP Care (HMO D-SNP) Amerihealth Caritas North Carolina, Inc. T5 Yes $0 NC
AmeriHealth Caritas VIP Care (HMO D-SNP) Amerihealth Michigan, Inc. T5 Yes $0 MI
Healthy Mississippi Premier Advantage (HMO-POS) Healthy Mississippi, Inc. T5 Yes $0 MS
CareOregon Advantage Plus (HMO D-SNP) Health Plan OF Careoregon, Inc. T5 Yes $0 OR
Samaritan Dual Advantage (HMO D-SNP) Samaritan Health Plans, Inc. T5 Yes $10.50 OR

Frequently Asked Questions

Is tadalafil 4 MG/ML Oral Suspension [Tadliq] covered by Medicare Part D?

Yes, tadalafil 4 MG/ML Oral Suspension [Tadliq] is covered by 33 Medicare Part D plans (0.7% of all Part D formularies).

What tier is tadalafil 4 MG/ML Oral Suspension [Tadliq] on Medicare Part D plans?

tadalafil 4 MG/ML Oral Suspension [Tadliq] averages Tier 4.3 across Part D plans, ranging from Tier 1 to Tier 5.

Does tadalafil 4 MG/ML Oral Suspension [Tadliq] require prior authorization?

100% of Part D formularies require prior authorization for tadalafil 4 MG/ML Oral Suspension [Tadliq]. Step therapy: 0%. Quantity limits: 75%.

How much does Medicare spend on tadalafil 4 MG/ML Oral Suspension [Tadliq]?

In 2023, total Medicare Part D spending on tadalafil 4 MG/ML Oral Suspension [Tadliq] was $95,218,190, covering 74,638 beneficiaries. The average spend per beneficiary was $1,275.73.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare